$Amazing $Biotech & $olid $Microcap $tocks

[ash111]

ONCS OncoSec Presents Positive Phase 2 Data for ImmunoPulse® IL-12 in Combination with Pembrolizumab Demonstrating a Best Overall Response Rate (BORR) of 50% in Predicted Anti-PD-1 Non-Responder Melanoma Patients

https://www.prnewswire.com/news-releases/oncosec-presents-positive-phase-2-data-for-immunopulse-il-12-in-combination-with-pembrolizumab-demonstrating-a-best-overall-response-rate-borr-of-50-in-predicted-anti-pd-1-non-responder-melanoma-patients-300539506.html

More solid facts: well positioned: $16m cash on hand, reasonable Cash burn rate ( $1.6m/ month), T.Assets/T.Liabilities Ratio=5, Solid.

Beside today's DATA ONCS will likely to provide updates relating Merck Partnership and more 2 Catalysts the near future.

Clinical Collaboration with Merck to Evaluate Combination of ImmunoPulse® IL-12 and KEYTRUDA® (pembrolizumab) for Metastatic Melanoma- happening right now.
https://www.clinicaltrials.gov/ct2/show/NCT03132675?term=NCT03132675.&rank=1 "

Upcoming Catalysts posted by Kei: http://investorshub.advfn.com/boards/read_msg.aspx?message_id=135411658